Great Ape Reservoirs of Human Malaria

人类疟疾的类人猿储存库

基本信息

  • 批准号:
    8186662
  • 负责人:
  • 金额:
    $ 68.59万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-09-20 至 2014-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Previous funding by an R03 application allowed us to develop novel methods that permit the amplification of Plasmodium sequences from fecal DNA. Screening ape samples from over 50 field sites throughout central Africa, we found that P. falciparum is of gorilla origin, and not of chimpanzee, bonobo or ancient human origin. We also found that chimpanzees and gorillas harbor at least nine Plasmodium species, including parasites that are near identical to P. vivax, P. ovale and P. malariae. Given the magnitude of this Plasmodium reservoir and the fact that gorilla P. falciparum has crossed the species to humans already once, the question arises whether additional cross-infections of ape Plasmodium parasites are occurring. This is of critical public health importance, not because such transmissions would be expected to contribute to current malaria morbidity and mortality, but because they would give an indication of the potential of ape malaria parasites to colonize humans should a reduction of P. falciparum transmission rates generate a new ecological niche. In this application, we will examine whether wild apes serve as a recurrent source of human malaria. We will continue to screen wild ape populations for Plasmodium infections, and test humans who live in close proximity to these apes for evidence of cross-species infection. Our hypothesis is that ape parasites have the potential to infect humans but fail to establish persistent infections because of the predominance of P. falciparum. Determining the types, locations and frequencies of ape Plasmodium cross-species infections will be critical to gauge the success of future P. falciparum eradication campaigns. 1. To determine the prevalence of P. vivax and other non-Laverania species in wild apes. We will determine the prevalence, host specificities and distribution of non-Laverania parasites in wild apes, and determine whether chimpanzees and/or gorillas represent a reservoir for human P. vivax in west central Africa. 2. To determine whether wild chimpanzees or gorillas serve as recurrent sources of human infection. We will use ultradeep (454) sequencing to screen humans who live in close proximity to wild apes for evidence of zoonotic Plasmodium infections. This approach will identify Laverania and non-Laverania parasites even if they infect humans at very low frequencies and in the context of multispecies infections. 3. To determine the natural history of ape Plasmodium infections. We will prospectively follow Plasmodium infected sanctuary apes to examine their clinical status, validate our non-invasive detection methods, and obtain blood samples for ape Plasmodium isolation and whole genome sequencing studies. 4. To determine the biological properties that distinguish human P. falciparum from related ape species. We will express ape Plasmodium erythrocyte binding ligands and test their ability to bind to human erythrocytes in order to investigate the molecular basis of Plasmodium host specificity and to assess which ape Plasmodium species have the capacity to cause a blood stage infection in humans. PUBLIC HEALTH RELEVANCE: Malaria is one of the most devastating infectious diseases in the world and one of the major global public health problems. This application will identify and molecularly characterize all Plasmodium species that infect chimpanzees, gorillas and bonobos in the wild, and determine whether these apes serve as a recurrent source for human infections. Knowledge gained from these studies will provide new insight into the evolution, biology and pathogenesis of human Plasmodium infections, and address questions critical to current eradication efforts of human malaria.
描述(由申请人提供):之前R03申请的资助允许我们开发新的方法,允许从粪便DNA中扩增疟原虫序列。通过对中非50多个地点的猿类样本进行筛选,我们发现恶性疟原虫起源于大猩猩,而不是黑猩猩、倭黑猩猩或古人类。我们还发现,黑猩猩和大猩猩体内至少有9种疟原虫,其中包括与间日疟原虫、卵形疟原虫和疟疾疟原虫几乎相同的寄生虫。考虑到这个疟原虫储存库的规模,以及大猩猩恶性疟原虫已经通过物种传播给人类一次的事实,问题出现了,猿疟原虫是否正在发生其他交叉感染。这对公共卫生至关重要,不是因为这种传播预计会导致目前的疟疾发病率和死亡率,而是因为它们将表明,如果恶性疟原虫传播率的降低产生新的生态位,类人猿疟疾寄生虫可能会在人类中定居。在这个应用程序中,我们将研究野生猿是否作为人类疟疾的复发源。我们将继续筛查野生猿类种群的疟原虫感染情况,并对生活在这些猿类附近的人类进行跨物种感染证据测试。我们的假设是猿寄生虫有可能感染人类,但由于恶性疟原虫的优势而无法建立持续感染。确定类人猿跨物种疟原虫感染的类型、地点和频率对于衡量未来根除恶性疟原虫运动的成功与否至关重要。1. 目的确定间日疟原虫和其他非狐猴属物种在野生类人猿中的流行情况。我们将确定非狐猴寄生虫在野生猿类中的流行率、宿主特异性和分布,并确定黑猩猩和/或大猩猩是否代表西非中部人类间日疟原虫的储存库。确定野生黑猩猩或大猩猩是否作为人类感染的复发源。我们将使用超深(454)测序来筛选生活在野生猿类附近的人类,以寻找人畜共患疟原虫感染的证据。这种方法将识别lavania和非lavania寄生虫,即使它们以非常低的频率在多物种感染的情况下感染人类。3. 确定猿猴疟原虫感染的自然历史。我们将对受疟原虫感染的保护区猿类进行前瞻性随访,以检验其临床状况,验证我们的非侵入性检测方法,并获得猿类疟原虫分离和全基因组测序的血液样本。4. 目的:确定人类恶性疟原虫与类人猿的生物学特性。我们将表达类人猿疟原虫红细胞结合配体并测试其与人类红细胞结合的能力,以研究疟原虫宿主特异性的分子基础,并评估哪些类人猿疟原虫有能力引起人类血期感染。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Beatrice H Hahn其他文献

Beatrice H Hahn的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Beatrice H Hahn', 18)}}的其他基金

Optimizing glycan shield coverage, germline B cell receptor binding and epitope diversity of V2-apex targeted HIV-1 Env immunogens
优化聚糖屏蔽覆盖、种系 B 细胞受体结合和 V2-apex 靶向 HIV-1 Env 免疫原的表位多样性
  • 批准号:
    10021396
  • 财政年份:
    2019
  • 资助金额:
    $ 68.59万
  • 项目类别:
Optimizing glycan shield coverage, germline B cell receptor binding and epitope diversity of V2-apex targeted HIV-1 Env immunogens
优化聚糖屏蔽覆盖、种系 B 细胞受体结合和 V2-apex 靶向 HIV-1 Env 免疫原的表位多样性
  • 批准号:
    10241429
  • 财政年份:
    2019
  • 资助金额:
    $ 68.59万
  • 项目类别:
Optimizing glycan shield coverage, germline B cell receptor binding and epitope diversity of V2-apex targeted HIV-1 Env immunogens
优化聚糖屏蔽覆盖、种系 B 细胞受体结合和 V2-apex 靶向 HIV-1 Env 免疫原的表位多样性
  • 批准号:
    10686018
  • 财政年份:
    2019
  • 资助金额:
    $ 68.59万
  • 项目类别:
Optimizing glycan shield coverage, germline B cell receptor binding and epitope diversity of V2-apex targeted HIV-1 Env immunogens
优化聚糖屏蔽覆盖、种系 B 细胞受体结合和 V2-apex 靶向 HIV-1 Env 免疫原的表位多样性
  • 批准号:
    10468221
  • 财政年份:
    2019
  • 资助金额:
    $ 68.59万
  • 项目类别:
Virus and Antibody Gene Sequencing Core
病毒和抗体基因测序核心
  • 批准号:
    10370981
  • 财政年份:
    2017
  • 资助金额:
    $ 68.59万
  • 项目类别:
Virus and Antibody Gene Sequencing Core
病毒和抗体基因测序核心
  • 批准号:
    10117168
  • 财政年份:
    2017
  • 资助金额:
    $ 68.59万
  • 项目类别:
Virus and Antibody Gene Sequencing Core
病毒和抗体基因测序核心
  • 批准号:
    10631869
  • 财政年份:
    2017
  • 资助金额:
    $ 68.59万
  • 项目类别:
Studies of the precursor of the human AIDS virus in its natural chimpanzee host
对黑猩猩天然宿主中人类艾滋病病毒前体的研究
  • 批准号:
    9186500
  • 财政年份:
    2015
  • 资助金额:
    $ 68.59万
  • 项目类别:
Restriction of HIV-1 transmission by type 1 interferons
1 型干扰素限制 HIV-1 传播
  • 批准号:
    8786805
  • 财政年份:
    2014
  • 资助金额:
    $ 68.59万
  • 项目类别:
Restriction of HIV-1 transmission by type 1 interferons
1 型干扰素限制 HIV-1 传播
  • 批准号:
    9275913
  • 财政年份:
    2014
  • 资助金额:
    $ 68.59万
  • 项目类别:

相似海外基金

A mixed methods approach to address multi-level barriers to care for migratory men living with HIV in South Africa
采用混合方法解决照顾南非艾滋病毒携带者移民男性的多层次障碍
  • 批准号:
    10403224
  • 财政年份:
    2022
  • 资助金额:
    $ 68.59万
  • 项目类别:
Using the EPIC model to build transdisciplinary communities of practice that effectively address urban resilience in Africa and Asia
使用 EPIC 模型建立跨学科实践社区,有效解决非洲和亚洲的城市复原力问题
  • 批准号:
    2103692
  • 财政年份:
    2022
  • 资助金额:
    $ 68.59万
  • 项目类别:
    Standard Grant
A mixed methods approach to address multi-level barriers to care for migratory men living with HIV in South Africa
采用混合方法解决照顾南非艾滋病毒携带者移民男性的多层次障碍
  • 批准号:
    10689689
  • 财政年份:
    2022
  • 资助金额:
    $ 68.59万
  • 项目类别:
Complex intervention to optimise adolescent BMI pre-conception to address the double burden of malnutrition: A RCT in rural and urban South Africa
优化青少年孕前体重指数以解决营养不良的双重负担的复杂干预措施:南非农村和城市的随机对照试验
  • 批准号:
    MR/V005790/1
  • 财政年份:
    2021
  • 资助金额:
    $ 68.59万
  • 项目类别:
    Research Grant
Complex intervention to optimise adolescent BMI pre-conception to address the double burden of malnutrition: A RCT in rural and urban South Africa
优化青少年孕前体重指数以解决营养不良的双重负担的复杂干预措施:南非农村和城市的随机对照试验
  • 批准号:
    MR/V005790/2
  • 财政年份:
    2021
  • 资助金额:
    $ 68.59万
  • 项目类别:
    Research Grant
An implementation science approach to address multi-level barriers to cancer screening among women living with HIV in South Africa
一种实施科学方法,以解决南非艾滋病毒感染妇女癌症筛查的多层次障碍
  • 批准号:
    10242935
  • 财政年份:
    2020
  • 资助金额:
    $ 68.59万
  • 项目类别:
A Multisectoral Strategy to Address Persistent Drivers of the HIV Epidemic in East Africa
解决东非艾滋病毒流行的持续驱动因素的多部门战略
  • 批准号:
    10267216
  • 财政年份:
    2020
  • 资助金额:
    $ 68.59万
  • 项目类别:
A Multisectoral Strategy to Address Persistent Drivers of the HIV Epidemic in East Africa
解决东非艾滋病毒流行的持续驱动因素的多部门战略
  • 批准号:
    10085144
  • 财政年份:
    2020
  • 资助金额:
    $ 68.59万
  • 项目类别:
A Multisectoral Strategy to Address Persistent Drivers of the HIV Epidemic in East Africa
解决东非艾滋病毒流行的持续驱动因素的多部门战略
  • 批准号:
    10438844
  • 财政年份:
    2020
  • 资助金额:
    $ 68.59万
  • 项目类别:
Teaching empowerment: Grass-roots educators' strategies to address gender equity in the context of the HIV epidemic in South Africa
教学赋权:基层教育工作者在南非艾滋病毒流行背景下解决性别平等问题的战略
  • 批准号:
    218055
  • 财政年份:
    2010
  • 资助金额:
    $ 68.59万
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了